Transfer of Analytical Methods according to USP <1224>

Why Should You Attend:

Analytical method transfer is a critical GMP activity that must be performed successfully before the receiving laboratory is considered qualified to run the method. Often, insufficient time is spent planning for method transfer and risks in the method transfer process may not have been adequately considered. This webinar will introduce the concept of quality risk management to the method transfer process. The four types of method transfer (comparative testing, covalidation, revalidation and transfer waiver) will be explained, together with considerations regarding transfer acceptance criteria. Common problems encountered during method transfer (including documentation, equipment, reagents and data processing) will be described, together with approaches to mitigate the risk of failure.

After attending this webinar, participants will be able to select the most appropriate and efficient method transfer approach for a given situation. They will also understand the potential risks involved in the method transfer process, together with the importance of identifying and mitigating them.

Areas Covered in the Webinar:

• Method transfer approaches
• Setting appropriate acceptance criteria
• Preparing for method transfer
• Is the method suitable?
• Managing risk in the method transfer process
• Common method transfer problems
• Contingency planning in the event of method transfer failure
• A risk-based approach to method transfer documentation

Who Will Benefit:

This webinar is intended for pharmaceutical scientists responsible for planning, executing or reviewing method transfer activities, including:

• Analytical development
• QC
• QA
• Regulatory affairs

Mark Powell
Director, Mark Powell Scientific Limited

Dr Mark Powell is a Fellow of the Royal Society of Chemistry (RSC) with over thirty years’ experience as an analytical chemist. Mark was Honorary Treasurer of the RSC’s Analytical Division and led a working group on continuing professional development until July 2016, when his term of office ended. Between 2003 and 2013, he was the Analytical Development Manager, and later Scientific Manager, of a UK-based contract research organization which specialized in early-stage oral drug development. In 2013, he set up Mark Powell Scientific Limited, which provides training and consultancy services to pharmaceutical companies. Mark has since enjoyed working with companies of all sizes around the world on a variety of training and consultancy assignments.

Follow us :